Wyeth can't keep Effexor settlements secret; AZ's nasal flu vax gets European rec;

 @FiercePharma: Woodcock: FDA may tighten generic-drug rules. Article | Follow @FiercePharma

> Handing Wyeth a setback in a patent infringement suit over its antidepressant Effexor XR, a federal judge says the pharmaceutical manufacturer can't claim its out-of-court settlements in earlier cases are confidential. Report

> AstraZeneca's nasal flu vaccine, already on sale in the U.S. as FluMist, has been recommended for pediatric approval in Europe, although it is unlikely to go on sale until 2012. Story

> Novo Nordisk launched its first consumer ad push for Victoza, its diabetes drug, with print ads and a refurbished website. Item

> K-V Pharmaceutical said it is opening a new generic drug business to replace its Ethex unit, which is being closed after a series of product recalls that resulted in criminal charges. K-V release | News

> Hospira is finally launching a generic version of Pfizer's injectable antibiotic Zosyn in the U.S. after years of trying. Article

Biotech News

 @FierceBiotech: The Top 10 Phase III Failures of 2010. Article | Follow @FierceBiotech

 @JohnCFierce: Lilly gets hit again. Teplizumab fails Ph3 for diabetes. MacroGenics gets hurt on this one as well. Article | Follow @JohnCFierce

> Aastrom puts hopes in promising CLI therapy. News

> Lilly's setbacks could lead to Amylin buyout, other deals. Article

> Dicerna gets another $4M for RNAi work. Report 

> Diamyd to divide operations. Story

> Group plots new biotech building in MD. Report

And Finally... GlaxoSmithKline is ramping up its solar-energy capacity at its Research Triangle, N.C., operations, adding another 220-kilowatt system next month. Report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.